Merck & Company Inc (MRK)vsPrecigen Inc (PGEN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PGEN
Precigen Inc
$6.85
+2.54%
HEALTHCARE · Cap: $2.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 77561% more annual revenue ($66.57B vs $85.72M). MRK leads profitability with a 4.8% profit margin vs -184.0%. PGEN earns a higher WallStSmart Score of 40/100 (F).
MRK
Hold36
out of 100
Grade: F
PGEN
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for PGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Strong operational efficiency at 41.2%
Revenue surging 6323.0% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Weak financial health signals
Trading at 57.1x book value
ROE of -1145.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PGEN
The strongest argument for PGEN centers on Operating Margin, Revenue Growth. Revenue growth of 6323.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PGEN
The primary concerns for PGEN are EPS Growth, Piotroski F-Score, Price/Book. Debt-to-equity of 2.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while PGEN is a hypergrowth play — different risk/reward profiles.
PGEN carries more volatility with a beta of 1.02 — expect wider price swings.
PGEN is growing revenue faster at 6323.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PGEN scores higher overall (40/100 vs 36/100) and 6323.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Precigen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?